Stockreport

Codiak BioSciences Reports Third Quarter 2022 Financial Results and Operational Progress

Codiak BioSciences, Inc.  (CDAK) 
PDF – Patient enrollment continuing in Phase 1 clinical trial of exoASO™-STAT6 in patients with advanced hepatocellular carcinoma; preliminary data anticipated during 1H 202 [Read more]